While binding to albumin may contribute to the targeted delivery of ruthenium compounds to cancer tissues due to the phenomenon known as Enhanced Permeability and Retention (EPR) effect [72] (due to the combination of leaky blood capillaries and lack of lymphatic drainage in tumors), binding to transferrin may constitute an “active” targeting route. This evidence concerns the gene TF and cancer.